|
|
Nanostructured Lipid Carrier (NLC) |
|
Vaxjo ID |
180 |
|
Vaccine Adjuvant Name |
Nanostructured Lipid Carrier (NLC) |
|
Adjuvant VO ID |
VO_0005476
|
|
Description |
a small molecule adjuvant that induces Th1-based immune response and is designed for use with self-amplifying RNA antigens |
|
Stage of Development |
Clinical Trial |
|
Location Licensed |
US (AAHI) |
|
Host Species for Testing |
2 |
|
Second Host Species for Testing |
3 |
|
Components |
oil core composed of solid (trimyristin) and liquid (squalene) lipids surrounded by surfactants (sorbitan monostearate and polysorbate 80) and a cationic lipid (DOTAP) |
|
Storage |
stable at 4C for at least 2 years in a liquid state |
|
Preparation |
mixing the lipids in an oil phase, dissolving the Tween 80 in citrate buffer aqueous phase, and homogenizing the two phases by micro-fluidization. The resulting emulsion is sterile-filtered and vialed until dilution in a sucrose-citrate solution and complexing with vaccine saRNA |
|
Function |
innate immune activation |
| References |
(Soza, 2025): Vaccine Adjuvant Compendium - VAC [https://vac.niaid.nih.gov/view?id=70]
Rice et al., 2022: Rice A, Verma M, Voigt E, Battisti P, Beaver S, Reed S, Dinkins K, Mody S, Zakin L, Tanaka S, Morimoto B, Olson CA, Gabitzsch E, Safrit JT, Spilman P, Casper C, Soon-Shiong P. Heterologous saRNA Prime, DNA Dual-Antigen Boost SARS-CoV-2 Vaccination Elicits Robust Cellular Immunogenicity and Cross-Variant Neutralizing Antibodies. Frontiers in immunology. 2022; 13; 910136. [PubMed: 35911728].
|
|
